Altimmune (ALT) Cash from Restructuring (2015 - 2016)

Altimmune (ALT) has reported Cash from Restructuring for 3 consecutive years, with -$66633.0 the latest figure, recorded in Q1 2017.

• In Q1 2017, Cash from Restructuring rose 66.13% year-over-year to -$66633.0; the TTM figure through Mar 2017 stood at -$267300.0 (up 83.35% YoY), while the FY2016 annual figure was -$397383.0, down 182.49% from the prior year.
• Cash from Restructuring held at -$66633.0 in Q1 2017 per ALT's latest filing, from -$66633.0 in the prior quarter.
• Across five years, Cash from Restructuring topped out at $1.9 million in Q1 2015 and bottomed at -$1.1 million in Q2 2015.
• Historically, Cash from Restructuring has averaged $7306.6 across 3 years, with a median of -$66727.0 in 2016.
• On a YoY basis, Cash from Restructuring climbed as much as 93.93% in 2016 and fell as far as 762.99% in 2016.
• Altimmune's Cash from Restructuring stood at -$319008.0 in 2015, then soared by 79.11% to -$66633.0 in 2016, then changed by 0.0% to -$66633.0 in 2017.
• Business Quant data shows ALT's Cash from Restructuring at -$66633.0 in Q1 2017, -$66633.0 in Q4 2016, and -$67307.0 in Q3 2016.